Brokerages Set Urogen Pharma (NASDAQ:URGN) Target Price at $33.00

Urogen Pharma (NASDAQ:URGN) has earned an average rating of “Moderate Buy” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $33.00.

A number of brokerages recently commented on URGN. Wall Street Zen raised Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research note on Monday, October 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research note on Monday, January 5th.

Urogen Pharma Trading Down 5.5%

Shares of NASDAQ URGN opened at $18.74 on Friday. Urogen Pharma has a 1 year low of $3.42 and a 1 year high of $30.00. The firm’s 50-day moving average is $23.74 and its 200-day moving average is $19.97. The firm has a market capitalization of $877.20 million, a PE ratio of -5.42 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.03. The business had revenue of $27.48 million during the quarter, compared to analyst estimates of $34.09 million. As a group, equities research analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 139,025 shares in the company, valued at $3,475,625. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

A number of large investors have recently bought and sold shares of URGN. Osaic Holdings Inc. boosted its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the period. State of Wyoming acquired a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $66,000. Russell Investments Group Ltd. raised its stake in shares of Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the period. Strs Ohio acquired a new position in shares of Urogen Pharma during the third quarter worth about $76,000. Finally, CWM LLC grew its holdings in shares of Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares in the last quarter. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.